Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + sacituzumab govitecan versus pembrolizumab alone as first-line treatment for PD-L1-high metastatic non-small cell lung cancer
jRCT2031230031Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + sacituzumab govitecan with Pembrolizumab monotherapy (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jul 2023; status: recruiting.
02
Drugs
pembrolizumabsacituzumab govitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031230031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230031.